

# Santos Castañeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6103635/publications.pdf>

Version: 2024-02-01

196  
papers

5,055  
citations

94269

37  
h-index

114278

63  
g-index

206  
all docs

206  
docs citations

206  
times ranked

5478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Desarrollo y viabilidad de cuatro checklists para la evaluación de la comorbilidad en pacientes con artritis reumatoide, espondiloartritis axial y artritis psoriásica: Proyecto GECHOAI. Reumatología Clínica, 2022, 18, 114-123.	0.2	2
2	Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECHOAI Project. Reumatología Clínica (English Edition), 2022, 18, 114-123.	0.2	1
3	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	0.9	7
4	Prevalence of Metabolic Syndrome in Psoriatic Arthritis. Journal of Clinical Rheumatology, 2022, 28, e388-e396.	0.5	1
5	Monitoring and safety of CAR-T therapy in clinical practice. Expert Opinion on Drug Safety, 2022, 21, 363-371.	1.0	0
6	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opinion on Drug Safety, 2022, 21, 311-333.	1.0	1
7	Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. Reumatología Clínica (English Edition), 2022, 18, 587-596.	0.2	3
8	Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 899-901.	0.5	3
9	Dermatomyositis associated with anti-MDA5 antibodies: A heterogenous clinical picture. Medicina Clínica (English Edition), 2022, 158, 186-186.	0.1	0
10	Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment. Genes, 2022, 13, 146.	1.0	3
11	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	16
12	Advances in the Treatment of Giant Cell Arteritis. Journal of Clinical Medicine, 2022, 11, 1588.	1.0	11
13	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. Clinical and Experimental Rheumatology, 2022, 40, 581-588.	0.4	2
14	Utility of tocilizumab in autoimmune eye diseases. Expert Opinion on Biological Therapy, 2022, 22, 789-799.	1.4	4
15	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	0
16	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
17	Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab. Reumatología Clínica (English Edition), 2022, , .	0.2	0
18	Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy, 2022, 22, 707-716.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152037.	1.6	6
20	Clinical evolution of antisyndetase syndrome after SARS-CoV2 infection: a 6-month follow-up analysis. <i>Clinical Rheumatology</i> , 2022, 41, 2601-2604.	1.0	6
21	Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature. <i>Rheumatology International</i> , 2022, 42, 1643-1652.	1.5	9
22	Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMATology (CARMA) prospective studyâ€”results at 5 years of follow-up. <i>Rheumatology</i> , 2021, 60, 2906-2915.	0.9	15
23	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	0.9	14
24	Biologic Therapy in COVID-19. <i>Archivos De Bronconeumologia</i> , 2021, 57, 1-2.	0.4	15
25	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. <i>Journal of Rheumatology</i> , 2021, 48, 741-750.	1.0	17
26	Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. <i>European Journal of Immunology</i> , 2021, 51, 634-647.	1.6	27
27	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	0.8	8
28	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110337.	1.2	5
29	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	1.3	5
30	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	0.8	7
31	Utilidad de la ecografÃa extraarticular aplicada a las enfermedades inflamatorias sistÃmicas en la prÃctica clÃnica. <i>ReumatologÃa ClÃnica</i> , 2021, 17, 229-236.	0.2	6
32	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 395-403.	1.6	14
33	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	1.3	5
34	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. <i>Arthritis Research and Therapy</i> , 2021, 23, 111.	1.6	7
35	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. <i>Observational multicenter study of 134 patients. Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	1.6	13
36	<i>HLA-B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Antiâ€“Carbamylated Protein Antibodyâ€“Positive/Antiâ€“Cyclic Citrullinated Peptideâ€“Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	2.9	12

#	ARTICLE	IF	CITATIONS
37	Dermatomiositis asociada a anticuerpos anti-MDA5, una entidad cl�nica heterog�nea. Medicina Cl�nica, 2021, 158, 186-186.	0.3	0
38	Respuesta a «Intersticiopat�a pulmonar subcl�nica en pacientes con esclerosis sist�mica. Estudio piloto sobre el papel del ultrasonido». Reumatolog�a Cl�nica, 2021, , .	0.2	0
39	Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases. Clinical Rheumatology, 2021, 40, 3547-3564.	1.0	17
40	S�ndrome de Cogan: an�lisis descriptivo y experiencia cl�nica de 7 casos diagnosticados y tratados en 2 hospitales de tercer nivel. Reumatolog�a Cl�nica, 2021, 17, 318-321.	0.2	2
41	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Scientific Reports, 2021, 11, 11510.	1.6	5
42	Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmunity Reviews, 2021, 20, 102830.	2.5	47
43	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Scientific Reports, 2021, 11, 16163.	1.6	1
44	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. Journal of Clinical Medicine, 2021, 10, 3704.	1.0	16
45	Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study. European Journal of Internal Medicine, 2021, 91, 63-69.	1.0	7
46	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatology and Therapy, 2021, 8, 1661-1675.	1.1	10
47	Volumetric BMD by 3D-DXA and Trabecular Bone Score in Adults With Down Syndrome. Journal of Clinical Densitometry, 2021, 24, 630-637.	0.5	4
48	Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. Journal of Clinical Medicine, 2021, 10, 382.	1.0	11
49	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. Arthritis Research and Therapy, 2021, 23, 268.	1.6	0
50	Response to «Subclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasound». Reumatolog�a Cl�nica (English Edition), 2021, , .	0.2	0
51	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 2021, 39, 612-620.	0.4	0
52	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.4	4
53	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 21-26.	0.4	3
54	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
55	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
56	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 69-75.	0.4	25
57	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 612-620.	0.4	8
58	Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-sectional Study. <i>Arthritis Care and Research</i> , 2020, 72, 822-828.	1.5	28
59	Reproducibility of Metacarpal Bone Mineral Density Measurements Obtained by Dual-Energy X-Ray Absorptiometry in Healthy Volunteers and Patients With Early Arthritis. <i>Journal of Clinical Densitometry</i> , 2020, 23, 678-684.	0.5	3
60	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 23-36.	1.3	16
61	Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. <i>Rheumatology</i> , 2020, 59, 3906-3916.	0.9	64
62	Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 17799.	1.6	10
63	Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. <i>Frontiers in Medicine</i> , 2020, 7, 601618.	1.2	67
64	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 897-901.	1.6	7
65	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 855-858.	1.3	0
66	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2816.	1.0	36
67	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	1.0	3
68	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 717-723.	1.4	20
69	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. <i>BMC Rheumatology</i> , 2020, 4, 42.	0.6	10
70	Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis. <i>Scientific Reports</i> , 2020, 10, 9636.	1.6	13
71	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1333-1338.	1.6	31
72	Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 608-615.	1.6	31

#	ARTICLE	IF	CITATIONS
73	Influence of MUC5B gene on antisynthetase syndrome. <i>Scientific Reports</i> , 2020, 10, 1415.	1.6	12
74	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.4	4
75	Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 662-669.	0.4	1
76	Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 166-170.	0.4	0
77	Giant cell arteritis: more than a cranial disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 15-17.	0.4	5
78	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.4	3
79	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 182-187.	0.4	0
80	Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1201-1205.	0.4	5
81	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.4	2
82	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	1.6	63
83	Facing arthritis: helping patients to handle their disease and concerns. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 903-905.	1.3	2
84	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	1.4	29
85	Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 258-263.	0.5	8
86	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. <i>Arthritis and Rheumatology</i> , 2019, 71, 2081-2089.	2.9	74
87	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 188-210.	0.2	5
88	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	2.0	15
89	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	2.0	17
90	Tocilizumab for the treatment of adult-onset Still's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 273-286.	1.4	37

#	ARTICLE	IF	CITATIONS
91	SAT0271â€¦RELATIONSHIP BETWEEN ANTI-MDA5 ANTIBODIES AND CANCER: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL AND MULTIDISCIPLINARY COHORT. , 2019, , .		0
92	FRI0006â€¦PROTECTIVE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) RS2495477 POLYMORPHISM IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SUBCLINICAL ATHEROSCLEROSIS. , 2019, , .		0
93	AB1201â€¦MANAGEMENT OF COMORBIDITY IN INFLAMMATORY ARTHRITIS: GECOAI PROJECT. , 2019, , .		0
94	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
95	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	1.0	36
96	Inhibidores de la vÃ±a de seÃ±alizaciÃ³n JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina ClÃ±nica, 2019, 152, 353-360.	0.3	8
97	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Seminars in Arthritis and Rheumatism, 2019, 49, 126-135.	1.6	66
98	Recomendaciones de la Sociedad EspaÃ±ola de ReumatologÃ±a sobre osteoporosis. ReumatologÃ±a ClÃ±nica, 2019, 15, 188-210.	0.2	40
99	The role of biologics in the treatment of giant cell arteritis. Expert Opinion on Biological Therapy, 2019, 19, 65-72.	1.4	6
100	Identification of a 3â€²â€²Untranslated Genetic Variant of <i><sc>RARB</sc></i> Associated With Carotid Intimaâ€¢Media Thickness in Rheumatoid Arthritis: A Genomeâ€¢Wide Association Study. Arthritis and Rheumatology, 2019, 71, 351-360.	2.9	26
101	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. Clinical Reviews in Allergy and Immunology, 2019, 56, 278-292.	2.9	13
102	Adherencia al tratamiento con fÃ¡rmacos moduladores de la enfermedad sintÃ©ticos en la artritis reumatoide. Resultados del estudio OBSERVAR. ReumatologÃ±a ClÃ±nica, 2019, 15, 264-270.	0.2	3
103	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 465-473.	0.4	19
104	Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment. Clinical and Experimental Rheumatology, 2019, 37, 615-622.	0.4	4
105	Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. Clinical and Experimental Rheumatology, 2019, 37, 731-739.	0.4	6
106	Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project. Clinical and Experimental Rheumatology, 2019, 37, 774-782.	0.4	2
107	Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. Arthritis and Rheumatology, 2018, 70, 975-976.	2.9	6
108	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. Current Rheumatology Reports, 2018, 20, 24.	2.1	44

#	ARTICLE	IF	CITATIONS
109	Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. <i>Autoimmunity Reviews</i> , 2018, 17, 301-315.	2.5	72
110	Interacciones farmacológicas de los anticuerpos monoclonales. <i>Medicina Clínica</i> , 2018, 151, 148-155.	0.3	4
111	New Criteria Needed for Antisynthetase Syndrome. <i>JAMA Neurology</i> , 2018, 75, 258.	4.5	13
112	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	1.6	123
113	Bone Mineral Density Distribution Curves in Spanish Adults With Down Syndrome. <i>Journal of Clinical Densitometry</i> , 2018, 21, 493-500.	0.5	16
114	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. <i>Reumatología Clínica</i> , 2018, 14, 346-359.	0.2	7
115	Tratamiento biológico en la enfermedad pulmonar intersticial difusa asociada a las enfermedades del tejido conectivo. <i>Archivos De Bronconeumología</i> , 2018, 54, 549-550.	0.4	0
116	Anakinra for the treatment of adult-onset Still's disease. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 979-992.	1.3	23
117	Rituximab in Takayasu arteritis: an unmet hope. <i>Rheumatology</i> , 2018, 57, 1133-1134.	0.9	4
118	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	0.9	6
119	Pharmacological interactions of monoclonal antibodies. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 148-155.	0.1	1
120	Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients. <i>PLoS ONE</i> , 2018, 13, e0202583.	1.1	25
121	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	1.3	17
122	Deregulated PSGL-1 Expression in B Cells and Dendritic Cells May Be Implicated in Human Systemic Sclerosis Development. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2123-2132.	0.3	17
123	Inflammatory Arthritis and Heart Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 262-280.	0.9	22
124	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.4	30
125	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	2.9	60
126	Respuesta. <i>Medicina Clínica</i> , 2017, 148, e15-e16.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 40303.	1.6	12
128	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	2.5	46
129	Osteoarthritis: More than Cartilage Degeneration. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2017, 15, 69-81.	1.3	15
130	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	1.6	52
131	Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. <i>Rheumatology International</i> , 2017, 37, 799-806.	1.5	37
132	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. <i>Rheumatology International</i> , 2017, 37, 1239-1248.	1.5	24
133	Innovations in the therapeutic outlook of rheumatoid arthritis. <i>Reumatología Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10 0,2 0		
134	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMATology study project. <i>Journal of Clinical Lipidology</i> , 2017, 11, 749-756.e3.	0.6	30
135	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
136	Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 10525.	1.6	14
137	Novedades en el panorama terapéutico de la artritis reumatoide. <i>Reumatología Clínica</i> , 2017, 13, 63-65.	0.2	0
138	Polymyalgia rheumatica. <i>Lancet</i> , The, 2017, 390, 1700-1712.	6.3	196
139	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	1.6	44
140	Fármacos biosimilares: un nuevo escenario en las terapias biológicas. <i>Reumatología Clínica</i> , 2017, 13, 287-293.	0.2	3
141	Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases. <i>Reumatología Clínica</i> , 2017, 13, 210-213.	0.2	9
142	Bone Mass Assessment in a Cohort of Adults With Down Syndrome: A Cross-Sectional Study. <i>Intellectual and Developmental Disabilities</i> , 2017, 55, 315-324.	0.6	15
143	Biosimilars: A New Scenario in Biologic Therapies. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 287-293.	0.2	3
144	Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis" by Bugatti et al.. <i>Arthritis Research and Therapy</i> , 2017, 19, 152.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 3-4.	0.4	5
146	Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases: comment on "Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative" by Baillet et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e55-e55.	0.5	2
147	Vitamin D and Autoimmune Rheumatic Diseases. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 356-357.	0.2	0
148	Vitamina D y enfermedades reumáticas. <i>Reumatología Clínica</i> , 2016, 12, 356-357.	0.2	0
149	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.	1.0	3
150	Adult-onset Still's disease: Advances in the treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 222-238.	1.4	91
151	Managing of giant cell arteritis and polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1133-1144.	0.5	6
152	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. <i>Autoimmunity Reviews</i> , 2016, 15, 1013-1030.	2.5	107
153	Adult-onset Still's disease. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 217-222.	0.1	1
154	Cardiovascular disease in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 851-869.	1.4	95
155	Giant Cell Arteritis: Visual Loss Is Our Major Concern. <i>Journal of Rheumatology</i> , 2016, 43, 1458-1461.	1.0	41
156	Why is Rheumatoid Arthritis Mortality Still High Despite the Advent of New Therapies? Comment on the Article by Widdifield et al. <i>Arthritis Care and Research</i> , 2016, 68, 726-727.	1.5	2
157	Gene polymorphisms and therapy in rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 225-229.	1.5	7
158	Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2016, 245, 139-142.	0.4	11
159	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0161727.	1.1	11
160	Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. <i>Arthritis Research and Therapy</i> , 2015, 17, 211.	1.6	25
161	Efficacy of Anakinra in Refractory Adult-Onset Still's Disease. <i>Medicine (United States)</i> , 2015, 94, e1554.	0.4	93
162	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. <i>Arthritis Research and Therapy</i> , 2015, 17, 102.	1.6	33

#	ARTICLE	IF	CITATIONS
163	A deletion at ADAMTS9-MAG11 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.5	18
164	Brief Report: Association of HLA-DRB1*01 With IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2015, 67, 823-827.	2.9	35
165	Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 445-458.	1.5	46
166	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 717-723.	1.6	114
167	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e20-e21.	1.6	0
168	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
169	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 618-626.	1.6	94
170	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis). <i>Arthritis Research and Therapy</i> , 2015, 17, 286.	1.6	11
171	An OA phenotype may obtain major benefit from bone-acting agents. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 421-428.	1.6	31
172	¿Es la reumatología una especialidad sostenible?. <i>Reumatología Clínica</i> , 2014, 10, 66-67.	0.2	0
173	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 1-8.	1.6	66
174	Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1659-1665.	2.9	115
175	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R146.	1.6	19
176	Lack of association between IL6 gene and Henoch-Schönlein purpura. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S141-2.	0.4	8
177	La Reumatología en la Comunidad de Madrid: disponibilidad actual de reumatólogos y necesidades futuras aplicando un modelo predictivo. <i>Reumatología Clínica</i> , 2013, 9, 353-358.	0.2	16
178	Estrogènes, arthrose et inflammation. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 350-356.	0.0	1
179	Update on the use of abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 599-621.	1.3	13
180	Estrogens, osteoarthritis and inflammation. <i>Joint Bone Spine</i> , 2013, 80, 368-373.	0.8	111

#	ARTICLE	IF	CITATIONS
181	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2012, 224, 426-429.	0.4	72
182	Subchondral bone remodelling and osteoarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	3
183	Subchondral bone as a key target for osteoarthritis treatment. <i>Biochemical Pharmacology</i> , 2012, 83, 315-323.	2.0	220
184	Differences in the management of early and established rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 172-178.	0.2	2
185	Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis. <i>PLoS ONE</i> , 2011, 6, e29492.	1.1	58
186	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.5	47
187	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. <i>Journal of Orthopaedic Research</i> , 2010, 28, 812-818.	1.2	26
188	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. <i>Arthritis Research and Therapy</i> , 2010, 12, R152.	1.6	180
189	A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. <i>Arthritis Research and Therapy</i> , 2010, 12, R50.	1.6	35
190	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 71-80.	1.6	130
191	Osteoarthritis associated with estrogen deficiency. <i>Arthritis Research and Therapy</i> , 2009, 11, 241.	1.6	236
192	Characterization of a new experimental model of osteoporosis in rabbits. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 53-59.	1.3	99
193	Reproducibility of Metacarpophalangeal Bone Mass Measurements Obtained by Dual-Energy X-Ray Absorptiometry in Healthy Volunteers and Patients With Early Arthritis. <i>Journal of Clinical Densitometry</i> , 2007, 10, 298-305.	0.5	15
194	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
195	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
196	Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9